Retrophin paid $1 million upfront to obtain licensing rights to Ligand Pharmaceuticals' clinical-stage dual acting receptor antagonist of angiotensin and endothelin receptors program. Retrophin plans to develop DARA as treatment for severe kidney disease and initially focal segmental glomerulosclerosis. Ligand could also receive more than $75 million in milestone fees plus 9% royalties.

Related Summaries